Renflexis

Active Ingredient(s): Infliximab-abda
FDA Approved: * April 21, 2017
Pharm Company: * SAMSUNG BIOEPSIS CO LTD
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Renflexis Overview

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.[2] It is given by slow injection into a vein, typically at six- to eight-week intervals.[2] Common side effects include infections, acute infusion reacti...

Read more Renflexis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Infliximab

Recent Renflexis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Infliximab-abda
  • Injection: 100mg, 100mg/vial
  • Vial: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Renflexis: (1 result)

Sorted by National Drug Code
  • 0006-4305 Renflexis 100 mg Intravenous Injection, Powder, Lyophilized, for Solution by Merck Sharp & Dohme Corp.

Other drugs which contain Infliximab-abda or a similar ingredient: (8 results)